triptorelin

(redirected from Decapeptyl)

triptorelin

 [trip″to-rel´in]
a synthetic analogue of gonadorelin that on prolonged administration suppresses gonadotropin release; used as triptorelin pamoate as an antineoplastic in the palliative treatment of prostatic carcinoma, administered intramuscularly.

triptorelin

Therapeutics A long-acting gonadotropin-releasing hormone analogue, that induces intense reversible hypogonadism by inhibiting LH and, to a lesser degree, FSH release, resulting in ↓ testosterone Indications Advanced prostate and ovarian CA; it may have a role in Rx-refractory sexual deviancy. See Paraphilia.

triptorelin

A synthetic gonadotrophin-releasing hormone used to treat advances cancer of the PROSTATE GLAND. A brand name is Decapeptyl SR.
References in periodicals archive ?
M2 PHARMA-June 14, 2019-Debiopharm and Ipsen Extend Their Strategic Decapeptyl (triptorelin)Partnership for Another 15 Years
In the routine protocol of the clinic of paediatric endocrinology outpatient; for the treatment of PP, GnRHa leuprolide (Lucrin 3.75 mg depot) or triptorelin (Decapeptyl 3.75 mg depot) is intramuscularly administered every 28 days with a dose of 3.75 mg if the patient has a weight >20 kg and with a dose of 1.875 mg if the patient has a weight <20 kg (2).
In patients undergoing GnRH agonist, depot decapeptyl 1.25 mg (Ferring, Germany) was administrated on the 21st day of previous cycle.
Debiopharm International has received approval for triptorelin 6-month formulation (Decapeptyl and Pamorelin 22.5mg) for the treatment of central precocious puberty (CPP) in 22 European countries, European Pharmaceutical Review revealed on Monday.
Down regulation of ovaries was done by gonadotrophin releasing hormone agonist (Injection DecaPeptyl) from Day 21 of previous cycle.
The 1- and 3-month formulations have already been registered in numerous countries and are available under different brand names: Trelstar, Decapeptyl and Pamorelin.
After initial consultation and screening of couples, long protocol with gonadotropin- releasing hormone agonist (GnRha) was given by daily injection DecaPeptyl from mid luteal phase of previous cycle.
After the surgery, PSA reduced to 0.1 ng/ml and he was planned to receive radiation therapy to the prostate bed followed by monthly decapeptyl. In November 2011, while still on androgen deprivation therapy with PSA=0.05 ng/ml, he developed dyspnea and hemoptysis.
"If Decapeptyl is used, the cost of one injection will make 1,966 som.